GradedCalls Analysts
Loading the ledger…
GradedCalls Analysts
Loading the ledger…
NYSE · Healthcare
AbbVie · Pharmaceuticals. Historical grades below use the calls in this ledger. The list is each analyst’s latest recommendation. The bar under it is the direction for grading, not a live street tally.
Direction for grading, from the latest active call of each analyst. Strong Buy, Buy, Overweight, and Outperform count as Buy. Hold, Neutral, and Equal-Weight count as Hold. Underperform, Underweight, and Sell count as Sell. The recommendation on the call — Target raise, Upgrade to Buy, Reiterate Overweight — is a separate label.
Overall factor · 2W
48.2/100Average of active call grades
GC score5/10GC 1→GC 10
GC 5–7. From 40 up to 70 is PROVISIONAL on the GC Scale.
The overall factor is the average of the 0–100 grades on active calls at this horizon. A call superseded by a later note on the same ticker within 90 days stays visible and does not enter this average, the GC score, or the hit rate. How this is computed
Active graded
| Analyst | Firm | N | Hit | Overall factor/100 · GC 1–10 |
|---|---|---|---|---|
| Gavin Clark-Gartner | Evercore | 1 | 100% | 100/10010/10 |
| Alexandria Hammond | Wolfe | 1 | 100% | 70/1008/10 |
| Gary Nachman | Canaccord | 1 | 100% | 70 |
These calls count toward the overall factor once the horizon has a price. An open window is listed and is not in the average yet.
| Date | Analyst | Recommendation | Directionfor grading | Target | Then | After | Return | Grade |
|---|---|---|---|---|---|---|---|---|
| Oct 9, 2026 | Michael YeeUBS | Target raise Desk rating stays Neutral | Hold | — | — | |||
| Oct 9, 2026 | Vamil DivanGuggenheim |
8
In this factor
Superseded
1
Visible, not scored
Hit rate
63%
Active calls only
If followed
+2.4%
Active directional calls
Active calls on ABBV were a full hit 63% of the time. Hit rate is not the rank.
| Mohit Bansal | Wells Fargo | 1 | 100% | 70/1008/10 |
| Rajesh Kumar | HSBC | 1 | 100% | 70/1008/10 |
| Navann Ty | BNP Paribas | 1 | 0% | 5.5/1001/10 |
| David Amsellem | Piper | 1 | 0% | 0/100—/10 EXIT LIQUIDITY |
| Steve Scala | TD Cowen | 1 | 0% | 0/100—/10 EXIT LIQUIDITY |
Desk rating stays Buy
| Buy |
| — |
| — |
| Oct 8, 2026 | Carter GouldCantor | Target raise Desk rating stays Overweight | Buy | — | — |
| Oct 7, 2026 Supersedes Supersedes prior call on Aug 3, 2026 (within 90 days). Prior call | Terence FlynnMorgan Stanley | Target raise Desk rating stays Overweight | Buy | — | — |
| Sep 10, 2026 | Rajesh KumarHSBC | Target raise Desk rating stays Buy | Buy | $263.50 | +4.0% | Hit |
| Aug 20, 2026 | David AmsellemPiper | Target raise Desk rating stays Overweight | Buy | $258.62 | -0.6% | Miss |
| Aug 17, 2026 | Mohit BansalWells Fargo | Target raise Desk rating stays Overweight | Buy | $254.86 | +2.4% | Hit |
| Aug 13, 2026 | Alexandria HammondWolfe | Upgrade to Outperform Desk rating Peer Perform → Outperform | Buy | $256.57 | +2.9% | Hit |
| Aug 11, 2026 | Navann TyBNP Paribas | Target raise Desk rating stays Neutral | Hold | $264.17 | +6.3% | Miss |
| Aug 10, 2026 | Gavin Clark-GartnerEvercore | Target raise Desk rating stays Outperform | Buy | $262.91 | +6.7% | Hit |
| Aug 3, 2026 | Gary NachmanCanaccord | Target raise Desk rating stays Buy | Buy | $248.80 | +2.1% | Hit |
| Jul 31, 2026 | Steve ScalaTD Cowen | Reiterate Buy Desk rating stays Buy | Buy | $247.94 | -0.6% | Miss |